TY - JOUR T1 - Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation JF - medRxiv DO - 10.1101/2020.04.29.20083717 SP - 2020.04.29.20083717 AU - Matthew C. Woodruff AU - Richard P. Ramonell AU - Kevin S. Cashman AU - Doan C. Nguyen AU - Ariel M. Ley AU - Shuya Kyu AU - Ankur Saini AU - Natalie Haddad AU - Weirong Chen AU - J. Christina Howell AU - Tugba Ozturk AU - Saeyun Lee AU - Jacob Estrada AU - Andrea Morrison-Porter AU - Andrew Derrico AU - Fabliha A. Anam AU - Henry Wu AU - Sang N. Le AU - Scott A. Jenks AU - William T. Hu AU - F. Eun-Hyung Lee AU - Ignacio Sanz Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/02/2020.04.29.20083717.abstract N2 - Wide heterogeneity of disease course ranging from asymptomatic spread1, 2 to respiratory failure and death3, 4 has become a hallmark of the SARS-CoV-2 (COVID-19) pandemic. While this clinical spectrum is well documented, its immunologic underpinnings are less clear. We have therefore initiated studies of the B cell responses as they would participate in both early effector responses and in the initiation of memory formation. In terms of effector responses, we were particularly interested in the engagement and clinical correlates of the extra-follicular pathway (EF) we recently described in flaring SLE5. In this systemic autoimmune disease, the EF pathway is initiated by newly activated naïve B cell (aN) leading to large expansion of autoantibody-producing antibody-secreting cells through the generation of an epigenetically primed B cell precursor which are double negative (DN) for naïve (IgD) and memory markers (CD27) and lacking expression of CXCR5 and CD21 (DN2)6, 7, 8. These highly activated D2 cells are also distinguished by high expression of CD11c and T-bet and are TLR7-driven. Both TLR7-stimulation which is triggered by ssRNA and the central role played by their murine counterparts (typically characterized as Age-Associated B cells), in viral clearance, strongly supported the hypothesis that DN2 cells and the global EF pathway could be prominently engaged in COVID-19 patients 9. Also of note, EF B cell activation is particularly prominent in SLE patients of African-American ancestry, a population disproportionately represented in severe COVID-19 6, 9In this study we find that critically ill patients with COVID-19 robustly upregulate B cells within the extrafollicular pathway, produce enormous numbers of antibody secreting cells, and lose unique transitional B cell populations that correlate with positive prognosis. This patient cluster associates tightly with biomarkers of poor outcomes and exhibits high rates of mortality. Thus, this B cell phenotype might serve as an immunological marker of severe COVID-19 infection at early stages and could therefore identify a patient subset likely to benefit from targeted immunomodulatory therapy aimed at alleviating disease burden.Competing Interest StatementDr. Hu reports personal fees from ViveBio, LLC, personal fees from AARP, Inc., personal fees from Biogen, Inc., grants from Fujirebio US, outside the submitted work; In addition, Dr. Hu has a patent CSF diagnosis of FTLD-TDP issued, and a patent CSF prognosis of SMA treatment pending. Dr. Lee is the founder of MicroB-plex, Inc and has research grants with Genentech.Funding StatementThis work was supported by National Institutes of Health grants: P01AI125180-01 (I.S); R37AI049660 (I.S); U19AI110483 (Emory Autoimmunity Center of Excellence, I.S, F.E.L); P01AI125180-04 (F.E.L); R37AI049660 (F.E.L); 1R01AI121252 (F.E.L); U01AI045969 (F.E.L); R01-AG054991 (W.T.H.); T32-HL116271-07 (R.P.R.)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRelevant human clinical data from the manuscript will be shared as required by the NIH upon formal acceptance to a peer-reviewed journal. ER -